From £6.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Advanced Oncotherapy – ‘Fesses Up at No-One-Is-Watching O’clock, BUT It Is Still Wrong!

By Nigel Somerville, the Deputy Sheriff of AIM | Wednesday 1 September 2021


Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


Back on August 17th I pointed out that according to AIM-listed Advanced Oncotherapy’s FY20 Annual Report, all the warrants exercisable at 25p issued back in July 2017 should have expired. Yet the night before, after-hours, the company had announced the exercise of 500,000 of those warrants. Last night the company slipped out an explanation at 6.14pm in its Result of GM announcement.

Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

 

ANP

Anpario – a recovery Buy?...

Thursday »

Cat_Fixing_Lightbulb

Bearcast issue update: all should be well

 

ORCP

Oracle Power: Cynical Foul

Time left: 23:28:26